Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R, S)-(±)-Sodium Ibuprofen Dihydrate - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R, S)-(±)-Sodium Ibuprofen Dihydrate
The racemic compound (R, S)-()-ibuprofen is a popular and well understood active pharmaceutical ingredient, but it has several disadvantageous formulation properties such as poor solubility, low melting point, and potential esterification with excipients containing an hydroxyl group. The authors investigate the use of an (R, S)-()-ibuprofen salt to evaluate these problems using various analytical methods to determine the polymorphism, crystallinity, and drying scheme.

Pharmaceutical Technology

Table IV: Enthalpy of dehydration, enthalpy of melting, and crystallinity of (R, S)-(6)-sodium ibuprofen dihydrate produced from seven of nine solvents arranged by the total ascending Hildebrand values.
To verify the solubility sphere, the DS–API values of n-propanol and cyclohexane were calculated using Equation 4. They were 18.18 and 35.24 MPa1/2, respectively indicating that n-propanol was inside the solubility sphere (18.18 MPa1/2 < 25.92 MPa1/2 ), but cyclohexane was outside (35.24 MPa1/2 > 25.92 MPa1/2 ). These calculations agreed with the experimental observations that (R, S)-()-sodium ibuprofen dihydrate dissolved well in n-propanol at 25 C with a solubility of 53 mg/mL but dissolved poorly in cyclohexane at 25 C with a solubility < 0.27 mg/mL.

Figure 7
Solids generated from all nine good solvents were isolated and analyzed with DCS, TGA, and PXRD. Solids, however, grown from benzyl alcohol and DMSO (two solvents with high-boiling points) were still wet after oven-drying in air at 40 C for 4 h and formed solvates with ill-defined DSC and TGA results. Only seven of nine solids could be represented by a typical DSC response of solids generated from water (see Figure 6). The wide-base endotherm from 50–100 C as supported by the boiling point of water and an approximately 13% weight loss in Figure 2 was corresponded to the enthalpy of dehydration. The enthalpies of dehydration (ΔHdehydration) of seven solvents are summarized in Table IV. The enthalpies of dehydration were 6.6–12.2 kcal/mol of water loss (23).

Figure 8
Based on the similar DSC response (see Figure 6) and weight-loss pattern (see Figure 2) for all solids grown from THF, n-butyl alcohol, IPA, DMF, ethanol, methanol, and water, only one pseudopolymorph was identified for (R, S)-()-sodium ibuprofen dihydrate. The typical DSC response (see Figure 6) showed that the chemically bonded water molecules sandwiched between a layer of all (R)-()-sodium ibuprofen molecules (R-layer) and a layer of all (S)-(–)-sodium ibuprofen molecules (S-layer) in the racemic (R, S)-()-sodium ibuprofen dihydrate compound were completely removed near 100 C (see Figure 2) (12).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here